Restoring the p53 ‘Guardian’ Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9

• DOI: 10.1016/j.tibtech.2018.01.014
• Publication Date: 2018-02-22T13:05:03Z
• Authors: Sergiu Chira; Diana Gulei; Amin Hajitou; Ioana Berindan-Ne...
• Keywords: EXPRESSION; 0301 basic medicine; AAVP tumor-target vector; tumor regression; Genetic Vectors; 610; PROTEIN; SURVIVIN PROMOTER; 09 Engineering; Mice; 03 medical and health sciences; 10 Technology; CRISPR-Associated Protein 9; Neoplasms; KNOCK-IN; BREAST-CANCER; Animals; Humans; CRISPR/Cas9; MUTANT P53; Cancer; Gene Editing; Science & Technology; GENE-THERAPY; Genetic Therapy; WILD-TYPE P53; 06 Biological Sciences; Prognosis; 3. Good health; Disease Models, Animal; Biotechnology & Applied Microbiology; Mutation; CRISPR-CAS9; CRISPR-Cas Systems; Tumor Suppressor Protein p53; Life Sciences & Biomedicine; SYSTEM; Biotechnology

With an increasing prevalence in the human population, cancer has become one of the most investigated fields of medicine. Among the potential targets for cancer therapy is the tumor suppressor gene TP53, which is found in a mutated state in approximately 50% of human cancers and is often associated with poor prognosis. We propose a novel, highly tumor-specific delivery system for TP53, based on the CRISPR/Cas9 genome editing technology. This system will restore the normal p53 phenotype in tumor cells by replacing the mutant TP53 gene with a functional copy, leading to sustained expression of p53 protein and tumor regression.